Integrating psychedelic-assisted psychotherapy into addiction care in the Czech Republic: Clinical evidence, safety, and regulatory developments
Zuzana Postránecká, Matyáš Lucký, Viktor Mravčík, Tomáš Páleníček
Journal of Psychedelic Studies June 12, 2026 Peer reviewed DOI: 10.1556/2054.2026.00514 via OpenAlex
Summary
Psychedelic-assisted psychotherapy (PAP) shows cautious clinical potential for treating substance use disorders (SUDs) in the Czech Republic, where high relapse rates and comorbidities are prevalent. The review highlights that while some randomized controlled studies provide strong evidence, much of the existing literature is observational or less rigorous. Recent developments include the integration of PAP into national guidelines and upcoming legislation for psilocybin use in medical settings, indicating a move toward pilot implementations.
Study at a glance
| Design | narrative review |
|---|---|
| Population | substance use disorder populations and dual-diagnosis individuals |
| Key finding | The strongest evidence for addiction treatment from psychedelic-assisted interventions comes from a limited number of randomized controlled studies, suggesting cautious clinical potential rather than established effectiveness. |
Abstract
Abstract The Czech Republic, like many European countries, continues to face significant challenges in treating substance use disorders (SUDs), with high relapse rates and complex comorbidities often linked to trauma and mental illness. Psychedelic-assisted psychotherapy (PAP) has re-emerged internationally as a promising therapeutic modality, although available evidence remains heterogeneous across substances, populations, and study designs. This narrative review critically examines clinical evidence relevant to psychedelic-assisted interventions in SUDs and selected dual-diagnosis populations, with particular attention to evidence quality, safety, and implementation constraints. It also contextualizes recent Czech developments, including ketamine-assisted psychotherapy initiatives, the inclusion of PAP in national addictology guidance, the publication of national psychiatry guidelines for psilocybin-assisted psychotherapy for medical use, and the 2025 legislative reform introducing psilocybin for medical use from January 2026. Across the reviewed literature, the strongest direct evidence for addiction treatment currently comes from a limited number of randomized and controlled studies, while much of the remaining literature remains observational, open-label, historical, or naturalistic. These findings suggest cautious clinical potential rather than established effectiveness across addiction care settings. Recent Czech legal and clinical developments may create a basis for carefully monitored pilot implementation and evaluation, but broader integration will depend on clearer indications, accredited training, longitudinal outcome monitoring, and transparent communication of both potential benefits and unresolved risks.